Aktuellt
SENASTE
Late last Friday, Isofol announced that the 300 PFS events triggering the analysis of the data of the ongoing phase III study will not be reached due to unusually high censoring of patients. The news sent the stock tumbling 27%. We understand the initial confusion in the market but highlight that this news should not negatively affect the possibility of a potential approval; nevertheless, the top line results might be delayed by a few months. We await the company’s analysis before making any adjustments to our assumptions.
LÄS MER
